David Tinkelman, MD
Favorite health tips: I read labels constantly, avoiding saturated fats. I make sure to walk 10,000 steps every day, which is a habit I started after we launched FitLogix.
Dr. Tinkelman is responsible for overall medical direction of our preventive health programs. He is board certified in both pediatrics and allergy and immunology, with more than 25 years' experience providing medical direction and quality assurance for disease management, quitline and wellness programs. Active in medical research, the author of over 135 journal publications and book chapters, and co-editor of four textbooks, all in respiratory disease, Dr. Tinkelman has expanded his research to include wellness and socioeconomic issues in health care. He currently serves on the Advisory Board for NAQC, and is a past president of the Joint Council of Asthma, Allergy and Immunology and a past Editor of the Journal of Asthma. Dr. Tinkelman previously served as a professor of pediatrics and vice president of health initiatives, and prior to that, was a practicing physician in Atlanta, GA, where he served as managing partner of his medical group. Dr. Tinkelman received his MD with Academic Honors from Hahnemann Medical College, and his BA from Temple University.
Thomas Yloija, MSW
Associate Clinical Director
Thomas is the associate clinical director for QuitLogix, the tobacco cessation program at National Jewish Health. He has with experience in smoking cessation, health care research, and practice with disparate populations. He will complete his Doctor of Philosophy in Social Work this summer at the University of Pittsburgh. Thomas received his Master of Social Work degree from the University of Toronto and his undergraduate degree from the University of Calgary. Ylioja has published more than a dozen peer reviewed research articles and presented at numerous conferences on substance use and tobacco cessation interventions in health care settings. He continues to collaborate nationally with clinical and population health researchers to expand access to tobacco treatment.